PhRMA: Cures Act Successor Should Include PAHPA, PRV Renewal

By Jessica Karins / August 9, 2024 at 2:56 PM
Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) and the review voucher program for pediatric rare diseases should be top priorities for future legislation on advancement of biomedical research, as well as policies to combat antimicrobial resistance, according to the drug makers’ lobby Pharmaceutical Research and Manufacturers of America (PhRMA) in a response to Reps. Diana DeGette (D-CO) and Larry Bucshon’s (R-IN) June letter to stakeholders asking for input on new legislation building on the Cures Act. PhRMA also...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.